{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:52:47Z","timestamp":1791406367429,"version":"4.3.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s11060-026-05772-4","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:40:16Z","timestamp":1788439216000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Annexin A2 associated with bevacizumab resistance and infiltrative escape in glioblastoma"],"prefix":"10.1007","volume":"179","author":[{"given":"Taketo","family":"Ezaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Takei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Teshigawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoichi","family":"Tomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuharu","family":"Akasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Murayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Toda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikaru","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihide","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"issue":"8","key":"5772_CR1","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021 Aug 2) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro-Oncology 23(8):1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106. PMID: 34185076; PMCID: PMC8328013","journal-title":"Neuro-Oncology"},{"issue":"8","key":"5772_CR2","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1308345","volume":"370","author":"OL Chinot","year":"2014","unstructured":"Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T (2014 Feb 20) Bevacizumab plus radiotherapy\u2013temozolomide for newly diagnosed glioblastoma. N Engl J Med 370(8):709\u2013722. https:\/\/doi.org\/10.1056\/NEJMoa1308345. PMID: 24552318","journal-title":"N Engl J Med"},{"issue":"8","key":"5772_CR3","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1308573","volume":"370","author":"MR Gilbert","year":"2014","unstructured":"Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ, Mehta MP (2014 Feb 20) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370(8):699\u2013708. https:\/\/doi.org\/10.1056\/NEJMoa1308573. PMID: 24552317; PMCID: PMC4201043","journal-title":"N Engl J Med"},{"issue":"32","key":"5772_CR4","doi-asserted-by":"publisher","first-page":"52423","DOI":"10.18632\/oncotarget.9387","volume":"7","author":"R Tamura","year":"2016","unstructured":"Tamura R, Tanaka T, Miyake K, Tabei Y, Ohara K, Sampetrean O, Kono M, Mizutani K, Yamamoto Y, Murayama Y, Tamiya T, Yoshida K, Sasaki H (2016 Aug 9) Histopathological investigation of glioblastomas resected under bevacizumab treatment. Oncotarget 7(32):52423\u201352435. https:\/\/doi.org\/10.18632\/oncotarget.9387. PMID: 27244880; PMCID: PMC5239563","journal-title":"Oncotarget"},{"issue":"2","key":"5772_CR5","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/cas.13889","volume":"110","author":"R Tamura","year":"2019","unstructured":"Tamura R, Tanaka T, Ohara K, Miyake K, Morimoto Y, Yamamoto Y, Kanai R, Akasaki Y, Murayama Y, Tamiya T, Yoshida K, Sasaki H (2019 Feb) Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab. Cancer Sci 110(2):499\u2013508. https:\/\/doi.org\/10.1111\/cas.13889. Epub 2018 Dec 21. PMID: 30467920; PMCID: PMC6361613","journal-title":"Cancer Sci"},{"issue":"61","key":"5772_CR6","doi-asserted-by":"publisher","first-page":"103890","DOI":"10.18632\/oncotarget.21978","volume":"8","author":"Y Yamamoto","year":"2017","unstructured":"Yamamoto Y, Tamura R, Tanaka T, Ohara K, Tokuda Y, Miyake K, Takei J, Akasaki Y, Yoshida K, Murayama Y, Sasaki H (2017 Oct 24) \u201cParadoxical\u201d findings of tumor vascularity and oxygenation in recurrent glioblastomas refractory to bevacizumab. Oncotarget 8(61):103890\u2013103899. https:\/\/doi.org\/10.18632\/oncotarget.21978. PMID: 29262608; PMCID: PMC5732774","journal-title":"Oncotarget"},{"issue":"12","key":"5772_CR7","doi-asserted-by":"publisher","first-page":"898614","DOI":"10.3389\/fonc.2022.898614","volume":"12","author":"J Takei","year":"2022","unstructured":"Takei J, Fukasawa N, Tanaka T, Yamamoto Y, Tamura R, Sasaki H, Akasaki Y, Kamata Y, Murahashi M, Shimoda M, Murayama Y (2022 Jun) Impact of Neoadjuvant Bevacizumab on Neuroradiographic response and histological findings related to tumor Stemness and the hypoxic tumor microenvironment in Glioblastoma: paired comparison between newly diagnosed and recurrent glioblastomas. Front Oncol 12(12):898614. https:\/\/doi.org\/10.3389\/fonc.2022.898614. PMID: 35785200; PMCID: PMC9247463","journal-title":"Front Oncol"},{"issue":"3","key":"5772_CR8","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s11060-023-04544-8","volume":"166","author":"T Tanaka","year":"2024","unstructured":"Tanaka T, Tamura R, Takei J, Morimoto Y, Teshigawara A, Yamamoto Y, Imai R, Kuranari Y, Tohmoto K, Hasegawa Y, Akasaki Y, Murayama Y, Miyake K, Sasaki H (2024 Feb) An exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma. J Neurooncol 166(3):557\u2013567. https:\/\/doi.org\/10.1007\/s11060-023-04544-8. Epub 2024 Jan 31. PMID: 38291182; PMCID: PMC10876816","journal-title":"J Neurooncol"},{"issue":"2","key":"5772_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s10014-024-00481-0","volume":"41","author":"T Ezaki","year":"2024","unstructured":"Ezaki T, Tanaka T, Tamura R, Ohara K, Yamamoto Y, Takei J, Morimoto Y, Imai R, Kuranai Y, Akasaki Y, Toda M, Murayama Y, Miyake K, Sasaki H (2024 Apr) Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment. Brain Tumor Pathol 41(2):61\u201372. https:\/\/doi.org\/10.1007\/s10014-024-00481-0. 10.1007\/s10014-024-00485-w. PMID: 38619734; PMCID: PMC11052834","journal-title":"Brain Tumor Pathol"},{"issue":"10","key":"5772_CR10","doi-asserted-by":"publisher","first-page":"346","DOI":"10.62347\/GQWP4029","volume":"17","author":"A Iwauchi","year":"2024","unstructured":"Iwauchi A et al. (2024 Oct 15) Comparative analyses of erythroblast transformation specific-1 related gene expression before and after neoadjuvant bevacizumab therapy for newly diagnosed glioblastoma. Int J Clin Exp Pathol 17(10):346\u2013359. https:\/\/doi.org\/10.62347\/GQWP4029. PMID: 39544713; PMCID: PMC11558313","journal-title":"Int J Clin Exp Pathol"},{"issue":"3","key":"5772_CR11","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1093\/neuonc\/not226","volume":"16","author":"E Tabouret","year":"2014","unstructured":"Tabouret E, Boudouresque F, Barrie M, Matta M, Boucard C, Loundou A, Carpentier A, Sanson M, Metellus P, Figarella-Branger D, Ouafik L, Chinot O (2014 Mar) Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma. Neuro-Oncology 16(3):392\u2013399. https:\/\/doi.org\/10.1093\/neuonc\/not226. Epub 2013 Dec 9. PMID: 24327581; PMCID: PMC3922517","journal-title":"Neuro-Oncology"},{"issue":"8","key":"5772_CR12","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1093\/neuonc\/nov094","volume":"17","author":"E Tabouret","year":"2015","unstructured":"Tabouret E, Boudouresque F, Farina P, Barri\u00e9 M, Bequet C, Sanson M, Chinot O (2015 Aug) MMP2 and MMP9 as candidate biomarkers to monitor bevacizumab therapy in high-grade glioma. Neuro Oncol 17(8):1174\u20131176. https:\/\/doi.org\/10.1093\/neuonc\/nov094. PMID: 26142442; PMCID: PMC4490881","journal-title":"Neuro Oncol"},{"issue":"19","key":"5772_CR13","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1212\/WNL.0000000000000402","volume":"82","author":"M Nowosielski","year":"2014","unstructured":"Nowosielski M, Wiestler B, Goebel G, Hutterer M, Schlemmer HP, Stockhammer G, Wick W, Bendszus M, Radbruch A (2014 May 13) Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma. Neurology 82(19):1684\u20131692. https:\/\/doi.org\/10.1212\/WNL.0000000000000402. Epub 2014 Apr 11. PMID: 24727314","journal-title":"Neurology"},{"issue":"7","key":"5772_CR14","doi-asserted-by":"publisher","first-page":"387","DOI":"10.2176\/nmc.ra.2016-0077","volume":"56","author":"T Ichikawa","year":"2016","unstructured":"Ichikawa T, Otani Y, Kurozumi K, Date I (2016 Jul 15) Phenotypic transition as a survival strategy of glioma. Neurol Med Chir(Tokyo) 56(7):387\u2013395. https:\/\/doi.org\/10.2176\/nmc.ra.2016-0077. Epub 2016 May 11. PMID: 27169497; PMCID: PMC4945597","journal-title":"Neurol Med Chir(Tokyo)"},{"issue":"10","key":"5772_CR15","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1016\/j.ejrad.2011.10.018","volume":"81","author":"F Yamasaki","year":"2012","unstructured":"Yamasaki F, Kurisu K, Aoki T, Yamanaka M, Kajiwara Y, Watanabe Y, Takayasu T, Akiyama Y, Sugiyama K (2012 Oct) Advantages of high b-value diffusion-weighted imaging to diagnose pseudo-responses in patients with recurrent glioma after bevacizumab treatment. Eur J Radiol 81(10):2805\u20132810. https:\/\/doi.org\/10.1016\/j.ejrad.2011.10.018. Epub 2011 Nov 17. PMID: 22100373","journal-title":"Eur J Radiol"},{"issue":"4","key":"5772_CR16","doi-asserted-by":"publisher","first-page":"414","DOI":"10.6004\/jnccn.2011.0038","volume":"9","author":"DA Reardon","year":"2011","unstructured":"Reardon DA, Turner S, Peters KB, Desjardins A, Gururangan S, Sampson JH, McLendon RE, Herndon JE, Jones LW, Kirkpatrick JP, Friedman AH, Vredenburgh JJ, Bigner DD, Friedman HS (2011 Apr) A review of VEGF\/VEGFR-targeted therapeutics for recurrent glioblastoma. J Natl Compr Canc Netw 9(4):414\u2013427. https:\/\/doi.org\/10.6004\/jnccn.2011.0038. PMID: 21464146; PMCID: PMC3399727","journal-title":"J Natl Compr Canc Netw"},{"issue":"7120","key":"5772_CR17","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/nature05236","volume":"444","author":"S Bao","year":"2006","unstructured":"Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN (2006 Dec 7) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444(7120):756\u2013760. https:\/\/doi.org\/10.1038\/nature05236. Epub 2006 Oct 18. PMID: 17051156","journal-title":"Nature"},{"issue":"2","key":"5772_CR18","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s12307-011-0064-9","volume":"4","author":"NA Lokman","year":"2011","unstructured":"Lokman NA, Ween MP, Oehler MK, Ricciardelli C (2011 Aug) The role of annexin A2 in tumorigenesis and cancer progression. Cancer Microenvironment 4(2):199\u2013208. https:\/\/doi.org\/10.1007\/s12307-011-0064-9. Epub 2011 Mar 5. PMID: 21909879; PMCID: PMC3170418","journal-title":"Cancer Microenvironment"},{"issue":"9","key":"5772_CR19","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/s41418-025-01494-8","volume":"32","author":"Y Tu","year":"2025","unstructured":"Tu Y, Xu L, Fu G, Wang J, Xia P, Tao Z, Ye Y, Hu J, Cai W, Zhu H, Wu Q, Ji J (2025 Sep) Lactylation-driven USP4-mediated ANXA2 stabilization and activation promotes maintenance and radioresistance of glioblastoma stem cells. Cell Death Differ 32(9):1648\u20131663. https:\/\/doi.org\/10.1038\/s41418-025-01494-8. Epub 2025 Apr 4. PMID: 40185997; PMCID: PMC12432172","journal-title":"Cell Death Differ"},{"issue":"10","key":"5772_CR20","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1515\/hsz-2016-0166","volume":"397","author":"W Liu","year":"2016","unstructured":"Liu W, Hajjar KA (2016 Oct 1) The annexin A2 system and angiogenesis. Biol Chem 397(10):1005\u20131016. https:\/\/doi.org\/10.1515\/hsz-2016-0166. PMID: 27366903","journal-title":"Biol Chem"},{"issue":"1","key":"5772_CR21","doi-asserted-by":"publisher","first-page":"11181","DOI":"10.1038\/s41598-022-14751-4","volume":"12","author":"L Liu","year":"2022","unstructured":"Liu L, Yang S, Lin K, Yu X, Meng J, Ma C, Wu Z, Hao Y, Chen N, Ge Q, Gao W, Wang X, Lam EW-F, Zhang L, Li F, Jin B, Jin D (2022 Jul 1) Sp1 induced gene TIMP1 is related to immune cell infiltration in glioblastoma. Sci Rep 12(1):11181. https:\/\/doi.org\/10.1038\/s41598-022-14751-4. PMID: 35778451; PMCID: PMC9249770","journal-title":"Sci Rep"},{"issue":"11","key":"5772_CR22","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.3390\/cancers11111651","volume":"11","author":"F Seker","year":"2019","unstructured":"Seker F, Cingoz A, Sur-Erdem \u0130, Erguder N, Erkent A, Uyulur F, Esai Selvan M, G\u00fcm\u00fc\u015f ZH, G\u00f6nen M, Bayraktar H, Wakimoto H, Bagci-Onder T (2019 Oct 25) Identification of SERPINE1 as a regulator of glioblastoma cell dispersal with transcriptome profiling. Cancers (Basel) 11(11):1651. https:\/\/doi.org\/10.3390\/cancers11111651. PMID: 31731490; PMCID: PMC6896086","journal-title":"Cancers (Basel)"},{"issue":"3","key":"5772_CR23","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.4049\/jimmunol.1500793","volume":"196","author":"B Renner","year":"2016","unstructured":"Renner B, Tong HH, Laskowski J, Jonscher K, Goetz L, Woolaver R, Hannan J, Li YX, Hourcade D, Pickering MC, Holers VM, Thurman JM (2016 Feb 1) Annexin A2 enhances complement activation by inhibiting factor H. J Immunol 196(3):1355\u20131365. https:\/\/doi.org\/10.4049\/jimmunol.1500793. Epub 2016 Jan 4. PMID: 26729803; PMCID: PMC4724541","journal-title":"J Immunol"},{"issue":"6","key":"5772_CR24","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.3892\/mmr.2011.573","volume":"4","author":"T Ezaki","year":"2011","unstructured":"Ezaki T, Sasaki H, Hirose Y, Miwa T, Yoshida K, Kawase T (2011 Nov-Dec) Molecular characteristics of pediatric non-ependymal, non\u2011pilocytic gliomas associated with resistance to temozolomide. Mol Med Rep 4(6):1101\u20131105. https:\/\/doi.org\/10.3892\/mmr.2011.573. Epub 2011 Aug 25. PMID: 21874248","journal-title":"Mol Med Rep"},{"issue":"10","key":"5772_CR25","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1158\/1078-0432.CCR-11-2390","volume":"18","author":"M DeLay","year":"2012","unstructured":"DeLay M, Jahangiri A, Carbonell WS, Hu Y-L, Tsao S, Tom MW, Paquette J, Tokuyasu TA, Aghi MK (2012 May 15) Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy. Clin Cancer Res 18(10):2930\u20132942. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-2390. Epub 2012 Apr 3. PMID: 22472177; PMCID: PMC3354006","journal-title":"Clin Cancer Res"},{"issue":"33","key":"5772_CR26","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1200\/JCO.23.01059","volume":"41","author":"PY Wen","year":"2023","unstructured":"Wen PY, van den Bent M, Youssef G, Cloughesy TF, Ellingson BM, Weller M, Galanis E, Barboriak DP, de Groot J, Gilbert MR, Huang R, Lassman AB, Mehta M, Molinaro AM, Preusser M, Rahman R, Shankar LK, Stupp R, Villanueva-Meyer JE, Wick W, Macdonald DR, Reardon DA, Vogelbaum MA, Chang SM (2023 Nov 20) RANO 2.0: update to the response assessment in neuro-oncology criteria for high- and low-grade gliomas in adults. J Clin Oncol 41(33):5187\u20135199. https:\/\/doi.org\/10.1200\/JCO.23.01059. Epub 2023 Sep 29. PMID: 37774317; PMCID: PMC10860967","journal-title":"J Clin Oncol"},{"issue":"3","key":"5772_CR27","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s10014-015-0216-6","volume":"32","author":"M Onishi","year":"2015","unstructured":"Onishi M, Ichikawa T, Kurozumi K, Inoue S, Maruo T, Otani Y, Fujii K, Ishida J, Shimazu Y, Yoshida K, Michiue H, Antonio Chiocca E, Date I (2015 Jul) Annexin A2 regulates angiogenesis and invasion phenotypes of malignant glioma. Brain Tumor Pathol 32(3):184\u2013194. https:\/\/doi.org\/10.1007\/s10014-015-0216-6. Epub 2015 Feb 20. PMID: 25697644","journal-title":"Brain Tumor Pathol"},{"issue":"2","key":"5772_CR28","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s10014-017-0284-x","volume":"34","author":"R Tamura","year":"2017","unstructured":"Tamura R, Tanaka T, Miyake K, Yoshida K, Sasaki H (2017 Apr) Bevacizumab for malignant gliomas: current indications, mechanisms of action and resistance, and markers of response. Brain Tumor Pathol 34(2):62\u201377. https:\/\/doi.org\/10.1007\/s10014-017-0284-x. Epub 2017 Apr 6. PMID: 28386777","journal-title":"Brain Tumor Pathol"},{"issue":"1","key":"5772_CR29","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s12672-024-01693-8","volume":"15","author":"S Weijie","year":"2024","unstructured":"Weijie S (2024 Dec 18) Annexin A2: the feasibility of being a therapeutic target associated with cancer metastasis and drug resistance in cancer microenvironment. Discov Oncol 15(1):783. https:\/\/doi.org\/10.1007\/s12672-024-01693-8. PMID: 39692932; PMCID: PMC11655786","journal-title":"Discov Oncol"},{"issue":"1","key":"5772_CR30","doi-asserted-by":"publisher","first-page":"20839","DOI":"10.1038\/s41598-021-00366-8","volume":"11","author":"K Ma","year":"2021","unstructured":"Ma K, Chen X, Liu W, Yang Y, Chen S, Sun J, Ma C, Wang T, Yang J (2021 Oct 21) ANXA2 is correlated with the molecular features and clinical prognosis of glioma, and acts as a potential marker of immunosuppression. Sci Rep 11(1):20839. https:\/\/doi.org\/10.1038\/s41598-021-00366-8. PMID: 34675316; PMCID: PMC8531374","journal-title":"Sci Rep"},{"issue":"8","key":"5772_CR31","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1038\/s41417-023-00627-w","volume":"30","author":"YX Song","year":"2023","unstructured":"Song YX, Li X, Nie SD, Hu Z-X, Zhou D, Sun D-Y, Zhou G-Y, Wang Y, Liu J-J, Song T, Wang S (2023 Aug) Extracellular vesicles released by glioma cells are decorated by Annexin A2 allowing for cellular uptake via heparan sulfate. Cancer Gene Ther 30(8):1156\u20131166. https:\/\/doi.org\/10.1038\/s41417-023-00627-w. Epub 2023 May 25. PMID: 37231059","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"5772_CR32","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","volume":"8","author":"ZL Liu","year":"2023","unstructured":"Liu ZL, Chen HH, Zheng LL, Sun LP, Shi L (2023 May 11) Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Sig Transduct Target Ther 8(1):198. https:\/\/doi.org\/10.1038\/s41392-023-01460-1. PMID: 37169756; PMCID: PMC10175505","journal-title":"Sig Transduct Target Ther"},{"issue":"40","key":"5772_CR33","doi-asserted-by":"publisher","first-page":"14346","DOI":"10.1523\/JNEUROSCI.3299-11.2011","volume":"31","author":"H Zhai","year":"2011","unstructured":"Zhai H, Acharya S, Gravanis I, Mehmood S, Seidman RJ, Shroyer KR, Hajjar KA, Tsirka SE (2011 Oct 5) Annexin A2 promotes glioma cell invasion and tumor progression. J Neurosci 31(40):14346\u201314360. https:\/\/doi.org\/10.1523\/JNEUROSCI.3299-11.2011. PMID: 21976520; PMCID: PMC3201988","journal-title":"J Neurosci"},{"issue":"10","key":"5772_CR34","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1182\/blood-2011-03-341214","volume":"118","author":"B Huang","year":"2011","unstructured":"Huang B, Deora AB, He KL, Chen K, Sui G, Jacovina AT, Almeida D, Hong P, Burgman P, Hajjar KA (2011 Sep 8) Hypoxia-inducible factor-1 drives annexin A2 system-mediated perivascular fibrin clearance in oxygen-induced retinopathy in mice. Blood 118(10):2918\u20132929. https:\/\/doi.org\/10.1182\/blood-2011-03-341214. Epub 2011 Jul 25. PMID: 21788340; PMCID: PMC3172807","journal-title":"Blood"},{"issue":"1","key":"5772_CR35","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40478-020-00916-7","volume":"8","author":"Y Matsumoto","year":"2020","unstructured":"Matsumoto Y, Ichikawa T, Kurozumi K, Otani Y, Fujimura A, Fujii K, Tomita Y, Hattori Y, Uneda A, Tsuboi N, Kaneda K, Makino K, Date I (2020 Apr 5) Annexin A2\u2013STAT3\u2013oncostatin M receptor axis drives phenotypic and mesenchymal changes in glioblastoma. Acta Neuropathol Commun 8(1):42. https:\/\/doi.org\/10.1186\/s40478-020-00916-7. PMID: 32248843; PMCID: PMC7132881","journal-title":"Acta Neuropathol Commun"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05772-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05772-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05772-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:03:45Z","timestamp":1791403425000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05772-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["5772"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05772-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-10073018\/v1","asserted-by":"object"}]},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"17 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. This study was also conducted according to institutional and national regulations and was approved by each institutional ethics committee (approval number N20050002 for Keio, JKI 018\u2013052 for Jikei, and 2018KH046 for Kagawa).","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"69"}}